Next-generation epidermal growth factor receptor tyrosine kinase inhibitors for leptomeningeal carcinomatosis

Kate W. Grimsrud, Maciej Mrugala

Research output: Contribution to journalArticle

Abstract

Introduction: Epidermal growth factor receptor (EGFR) mutation status is strongly correlated with leptomeningeal carcinomatosis in non-small cell lung cancer. Historically, patients were treated with radiotherapy, intrathecal chemotherapy or first-generation EGFR tyrosine kinase inhibitors (TKIs); however, most would eventually develop resistance and disease progression. Therefore, recent interest has sparked in investigating next-generation EGFR-TKI monotherapy. Case reports: We describe 2 patients with non-small cell lung adenocarcinoma who later presented with leptomeningeal disease, treated with next-generation EGFR-TKI monotherapy, independent of whole-brain radiotherapy, with favorable response and outcome. Conclusions: The next-generation EGFR-TKIs may have improved success in treatment of leptomeningeal metastases in non-small cell lung adenocarcinoma when compared with the first-generation and second-generation EGFR-TKIs. Next-generation EGFR-TKI monotherapy should be considered in select patients with leptomeningeal metastases from lung adenocarcinoma. More research is needed to review this potential therapeutic option, especially for use as first-line therapy.

Original languageEnglish (US)
Pages (from-to)59-61
Number of pages3
JournalNeurologist
Volume24
Issue number2
DOIs
StatePublished - Mar 1 2019

Fingerprint

Meningeal Carcinomatosis
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Radiotherapy
Neoplasm Metastasis
Non-Small Cell Lung Carcinoma
Disease Progression
Therapeutics
Drug Therapy
Mutation
Brain

Keywords

  • afatinib
  • epidermal growth factor receptor
  • leptomeningeal carcinomatosis
  • osimertinib

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Next-generation epidermal growth factor receptor tyrosine kinase inhibitors for leptomeningeal carcinomatosis. / Grimsrud, Kate W.; Mrugala, Maciej.

In: Neurologist, Vol. 24, No. 2, 01.03.2019, p. 59-61.

Research output: Contribution to journalArticle

@article{949a2bdff7d14d798d6140c1eb6cecf0,
title = "Next-generation epidermal growth factor receptor tyrosine kinase inhibitors for leptomeningeal carcinomatosis",
abstract = "Introduction: Epidermal growth factor receptor (EGFR) mutation status is strongly correlated with leptomeningeal carcinomatosis in non-small cell lung cancer. Historically, patients were treated with radiotherapy, intrathecal chemotherapy or first-generation EGFR tyrosine kinase inhibitors (TKIs); however, most would eventually develop resistance and disease progression. Therefore, recent interest has sparked in investigating next-generation EGFR-TKI monotherapy. Case reports: We describe 2 patients with non-small cell lung adenocarcinoma who later presented with leptomeningeal disease, treated with next-generation EGFR-TKI monotherapy, independent of whole-brain radiotherapy, with favorable response and outcome. Conclusions: The next-generation EGFR-TKIs may have improved success in treatment of leptomeningeal metastases in non-small cell lung adenocarcinoma when compared with the first-generation and second-generation EGFR-TKIs. Next-generation EGFR-TKI monotherapy should be considered in select patients with leptomeningeal metastases from lung adenocarcinoma. More research is needed to review this potential therapeutic option, especially for use as first-line therapy.",
keywords = "afatinib, epidermal growth factor receptor, leptomeningeal carcinomatosis, osimertinib",
author = "Grimsrud, {Kate W.} and Maciej Mrugala",
year = "2019",
month = "3",
day = "1",
doi = "10.1097/NRL.0000000000000220",
language = "English (US)",
volume = "24",
pages = "59--61",
journal = "Neurologist",
issn = "1074-7931",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Next-generation epidermal growth factor receptor tyrosine kinase inhibitors for leptomeningeal carcinomatosis

AU - Grimsrud, Kate W.

AU - Mrugala, Maciej

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Introduction: Epidermal growth factor receptor (EGFR) mutation status is strongly correlated with leptomeningeal carcinomatosis in non-small cell lung cancer. Historically, patients were treated with radiotherapy, intrathecal chemotherapy or first-generation EGFR tyrosine kinase inhibitors (TKIs); however, most would eventually develop resistance and disease progression. Therefore, recent interest has sparked in investigating next-generation EGFR-TKI monotherapy. Case reports: We describe 2 patients with non-small cell lung adenocarcinoma who later presented with leptomeningeal disease, treated with next-generation EGFR-TKI monotherapy, independent of whole-brain radiotherapy, with favorable response and outcome. Conclusions: The next-generation EGFR-TKIs may have improved success in treatment of leptomeningeal metastases in non-small cell lung adenocarcinoma when compared with the first-generation and second-generation EGFR-TKIs. Next-generation EGFR-TKI monotherapy should be considered in select patients with leptomeningeal metastases from lung adenocarcinoma. More research is needed to review this potential therapeutic option, especially for use as first-line therapy.

AB - Introduction: Epidermal growth factor receptor (EGFR) mutation status is strongly correlated with leptomeningeal carcinomatosis in non-small cell lung cancer. Historically, patients were treated with radiotherapy, intrathecal chemotherapy or first-generation EGFR tyrosine kinase inhibitors (TKIs); however, most would eventually develop resistance and disease progression. Therefore, recent interest has sparked in investigating next-generation EGFR-TKI monotherapy. Case reports: We describe 2 patients with non-small cell lung adenocarcinoma who later presented with leptomeningeal disease, treated with next-generation EGFR-TKI monotherapy, independent of whole-brain radiotherapy, with favorable response and outcome. Conclusions: The next-generation EGFR-TKIs may have improved success in treatment of leptomeningeal metastases in non-small cell lung adenocarcinoma when compared with the first-generation and second-generation EGFR-TKIs. Next-generation EGFR-TKI monotherapy should be considered in select patients with leptomeningeal metastases from lung adenocarcinoma. More research is needed to review this potential therapeutic option, especially for use as first-line therapy.

KW - afatinib

KW - epidermal growth factor receptor

KW - leptomeningeal carcinomatosis

KW - osimertinib

UR - http://www.scopus.com/inward/record.url?scp=85062397794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062397794&partnerID=8YFLogxK

U2 - 10.1097/NRL.0000000000000220

DO - 10.1097/NRL.0000000000000220

M3 - Article

C2 - 30817492

AN - SCOPUS:85062397794

VL - 24

SP - 59

EP - 61

JO - Neurologist

JF - Neurologist

SN - 1074-7931

IS - 2

ER -